The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: US Stocks Seen Lower On Earnings, Ahead Of Data

Wed, 30th Apr 2014 12:04

LONDON (Alliance News) - US equities are set to open marginally lower Wednesday, as investors digest the latest tranche of quarterly trading statements released after the Wall Street close on Tuesday, and ahead of some important US macroeconomic data and the latest Federal Open Market Committee policy meeting decisions.

"US markets look set to open lower Wednesday as earnings from Twitter and eBay after the close yesterday pointed to lower-than-expected future growth," says Jasper Lawler, market analyst at CMC Markets.

Online retailer eBay posted a net loss of USD2.3 billion, or USD1.82 per share, in the first quarter, compared with net income of USD677 million in the same quarter last year. Although its quarterly earnings per share, excluding items, as well as quarterly revenue came in above analysts' expectations, the company's second-quarter guidance was weak.

Meanwhile, Twitter posted a net loss of USD132 million, or USD23 cents per share, in the first quarter, compared to a net loss of USD27 million in the same period last year. The company also issued 2014 revenue guidance that was lukewarm.

Twitter is down 13% in pre-market trading, while eBay is down 4.3%.

"Also playing into today's cautious approach from investors is likely to be the amount of important data releases lined up, not to mention the FOMC decision later on," says Craig Erlam, market analyst at Alpari.

"We've just come off two very good days, it is only logical to lock in some profits when there is GDP and ADP employment data and a central bank decision to come," he adds.

Ahead of the New York bell, the NASDAQ Composite is called to open down 0.3%, while the DJIA and S&P 500 are indicated to open marginally lower.

ADP employment change is released at 1215 GMT. Economists' expectations are for the reading, which is often regarded as indicative of the highly anticipated non-farm payrolls data released later in the week, to show that the private sector to have added 210,000 jobs compared to the 191,000 jobs added in March.

The preliminary reading of US first quarter GDP is published at 1230 GMT. This is "widely expected to be disappointing after the deep-freeze US winter," said Michael Hewson, chief market analyst at CMC Markets. An annualised reading of 1.2% is expected, down from 2.6% in the fourth quarter of last year.

The Chicago purchasing managers' index is released at 1345 GMT.

Later in the day, the US Federal Open Market Committee publishes its latest interest rate and monetary policy decisions at 1800 GMT.

In the UK, stocks continue to trade mixed. The FTSE 100 is up 0.2% at 6,786.08, the FTSE 250 is down 0.5% at 15,820.14, and the AIM All-Share index is up 0.8% at 822.28.

At the individual stock level, GlaxoSmithKline has just released its results for the first quarter of 2014. The drugs giant reported a drop in revenue and net profit for the quarter due to asset sales and a decline in sales of pharmaceuticals in the US, but the company also raised its dividend and reiterated its full-year profit guidance despite making its sales guidance more vague.

Its net profit fell to GBP668 million in the three months to end-March from GBP961 million a year earlier, as revenue declined to GBP5.61 billion from GBP6.47 billion. That was mainly due to asset sales and masked lower costs that resulted from its restructuring programme.

The company is is currently one of the biggest fallers in the blue-chip index, down 1.4%.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.